Epizyme, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2008, Epizyme has made significant strides in the field of epigenetics, focusing on the discovery and development of small molecule drugs that target specific genetic mutations. The company’s flagship product, Tazemetostat, is a first-in-class EZH2 inhibitor that has garnered attention for its unique mechanism of action and potential to treat various malignancies. With a strong commitment to advancing precision medicine, Epizyme has established a notable market position, particularly in the oncology sector, and continues to expand its pipeline of targeted therapies. Through its dedication to scientific excellence, Epizyme is shaping the future of cancer treatment and improving patient outcomes.
We don't have data for Epizyme, Inc., but we can show you information about their parent organization instead.
View parent company